Skip to content

Study · Case report or series · n = 1 · 2025

3 results

From weight loss to muscle loss: rhabdomyolysis linked to semaglutide.

Jadvani R, Singh M

Clinical kidney journal22 Nov 2025Cited by 1 (Europe PMC)

PMID41383908 (opens in a new tab)PMCIDPMC12690205 (opens in a new tab)DOI10.1093/ckj/sfaf356 (opens in a new tab)PepBankPUB-41383908
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 36-year-old obese man, rhabdomyolysis occurred 6 days after the weekly semaglutide dose was raised from 1.7 mg to 2.4 mg.

    In plain wordsIn one obese man, muscle breakdown occurred 6 days after his weekly semaglutide dose was raised.

    Peptide
    Semaglutide
    Outcome
    IncreaseRhabdomyolysis
    Study

    n = 1

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    2.4 mg weekly (increased from 1.7 mg)As given in this study (human).

    Source sentences

    Summary
    We report a case of semaglutide-associated rhabdomyolysis in a 36-year-old obese male who presented with bilateral lower extremity pain, cramping and dark urine 6 days after increasing his weekly dose from 1.7 mg to 2.4 mg.
    1 context sentence
    Summary · context
    After excluding other common causes through clinical assessment and diagnostic workup, this case underscores the importance of recognizing this rare but potentially serious adverse effect of semaglutide.
  2. 02HumanCase report or seriesSafety outcome

    In a 36-year-old obese man on semaglutide 2.4 mg weekly, creatine kinase was markedly elevated at 16 202 U/L.

    In plain wordsIn one obese man on semaglutide, a blood marker of muscle damage was far above the normal range.

    Peptide
    Semaglutide
    Outcome
    IncreaseCreatine kinase
    Study

    n = 1

    Outcome group
    Adverse events · Musculoskeletal
    Studied dose
    2.4 mg weekly (increased from 1.7 mg)As given in this study (human).

    Measurements

    CK
    16,202 U/L
    normal range 20-200 U/L

    Source sentences

    Summary
    Laboratory evaluation revealed markedly elevated CK (16 202 U/L; normal: 20-200 U/L) and liver enzymes (aspartate aminotransferase: 279 U/L, alanine aminotransferase: 77 U/L), consistent with rhabdomyolysis.
    1 context sentence
    Summary · context
    We report a case of semaglutide-associated rhabdomyolysis in a 36-year-old obese male who presented with bilateral lower extremity pain, cramping and dark urine 6 days after increasing his weekly dose from 1.7 mg to 2.4 mg.
  3. 03HumanCase report or seriesSafety outcome

    In a 36-year-old obese man on semaglutide 2.4 mg weekly, aspartate aminotransferase was 279 U/L and alanine aminotransferase was 77 U/L.

    In plain wordsIn one obese man on semaglutide, liver enzyme levels were raised.

    Peptide
    Semaglutide
    Outcome
    IncreaseLiver enzymes (AST and ALT)
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    2.4 mg weekly (increased from 1.7 mg)As given in this study (human).

    Measurements

    AST
    279 U/L
    case
    ALT
    77 U/L
    case

    Source sentences

    Summary
    Laboratory evaluation revealed markedly elevated CK (16 202 U/L; normal: 20-200 U/L) and liver enzymes (aspartate aminotransferase: 279 U/L, alanine aminotransferase: 77 U/L), consistent with rhabdomyolysis.
    1 context sentence
    Summary · context
    We report a case of semaglutide-associated rhabdomyolysis in a 36-year-old obese male who presented with bilateral lower extremity pain, cramping and dark urine 6 days after increasing his weekly dose from 1.7 mg to 2.4 mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.